Stock Events

Stock Events

Acurx Pharmaceuticals 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-2.32
-1.76
-1.2
-0.64
Expected EPS
-1.0162799999999999
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2021
2022
2023
2024
0Revenue
-26.75MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 3ZO0.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap300.2B
Merck & Co., Inc. is a global healthcare company that develops antibiotics and treatments for infectious diseases, directly competing with Acurx's focus on developing novel antibiotics.
Pfizer
PFE
Mkt Cap153.13B
Pfizer Inc. is involved in the discovery, development, and manufacture of healthcare products including antibiotics, making it a competitor in the infectious disease space.
GSK
GSK
Mkt Cap116.3B
GlaxoSmithKline plc engages in the creation and discovery of pharmaceutical products, including antibiotics, competing in the same market as Acurx Pharmaceuticals.
Abbvie
ABBV
Mkt Cap367.8B
AbbVie Inc. researches and develops a broad range of pharmaceuticals including treatments for infectious diseases, positioning it as a competitor.
Johnson & Johnson
JNJ
Mkt Cap574.66B
Johnson & Johnson engages in the research and development of pharmaceuticals, including those for infectious diseases, making it a competitor in the healthcare sector.
Novartis
NVS
Mkt Cap297.35B
Novartis AG focuses on the discovery, development, and marketing of healthcare products, including antibiotics, which places it in competition with Acurx.
AMGEN
AMGN
Mkt Cap189.22B
Amgen Inc. is a biotechnology company that develops innovative human therapeutics, including treatments for infections, competing in the biopharmaceutical space.
Bristol-Myers Squibb
BMY
Mkt Cap119.69B
Bristol-Myers Squibb Company discovers, develops, and delivers innovative medicines, including those for infectious diseases, competing with Acurx's product pipeline.
Sanofi
SNY
Mkt Cap113.88B
Sanofi engages in the research, development, and marketing of pharmaceutical products, including antibiotics, making it a direct competitor.
Astrazeneca
AZN
Mkt Cap316.3B
AstraZeneca PLC is a global, science-led biopharmaceutical company that develops a range of pharmaceuticals, including those for bacterial infections, directly competing with Acurx Pharmaceuticals.

About

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Show more...
CEO
ISIN
US00510M2035
WKN
000A41DXH

Listings

F
DE
3ZO0.F
XNAS
US
ACXP
STU
DE
3ZO0.STU
MU
DE
3ZO0.MU

0 Comments

Share your thoughts

FAQ

What is Acurx Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Acurx Pharmaceuticals stocks are traded under the ticker 3ZO0.F.
When is the next Acurx Pharmaceuticals earnings date?▼
Acurx Pharmaceuticals is going to release the next earnings report on May 07, 2026.
What were Acurx Pharmaceuticals earnings last quarter?▼
3ZO0.F earnings for the last quarter are -0.64 EUR per share, whereas the estimation was -0.89 EUR resulting in a +27.96% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Acurx Pharmaceuticals revenue for the last year?▼
Acurx Pharmaceuticals revenue for the last year amounts to 0 EUR.
What is Acurx Pharmaceuticals net income for the last year?▼
3ZO0.F net income for the last year is -26.75M EUR.
In which sector is Acurx Pharmaceuticals located?▼
Acurx Pharmaceuticals operates in the Other sector.
When did Acurx Pharmaceuticals complete a stock split?▼
The last stock split for Acurx Pharmaceuticals was on August 05, 2025 with a ratio of 1:20.